Emina Vorkapic1, Elma Dugic1, Svante Vikingsson1, Joy Roy2, Mikko I Mäyränpää3, Per Eriksson4, Dick Wågsäter5. 1. Division of Drug Research, Department of Medical and Health Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. 2. Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 3. Department of Pathology, University of Helsinki, Helsinki, Finland; HUSLAB, Division of Pathology, Meilahti Laboratories of Pathology, Helsinki University Central Hospital, Helsinki, Finland. 4. Atherosclerosis Research Unit, Center for Molecular Medicine, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. 5. Division of Drug Research, Department of Medical and Health Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. Electronic address: dick.wagsater@liu.se.
Abstract
BACKGROUND: Abdominal aortic aneurysm (AAA) is characterized by vascular remodeling with increased infiltration of inflammatory cells and apoptosis/modulation of vascular smooth muscle cells (SMCs). Imatinib is a selective inhibitor of several tyrosine kinases, including PDGF receptors, Abl, and c-kit. The objective of this study was to characterize the potential protective role of imatinib on AAA development and the molecular mechanisms involved. METHODS: Male ApoE(-/-) mice were infused with angiotensin (Ang) II (1000 ng/kg/min) for 4 weeks to induce AAA or saline as controls. Daily treatment with 10 mg/kg imatinib, or tap water as control, was provided via gavage for 4 weeks. RESULTS: Treatment with imatinib was found to decrease the aortic diameter and vessel wall thickness, mediated by multiple effects. Imatinib treatment in AngII infused mice resulted in a reduced cellular infiltration of CD3ε positive T lymphocytes by 86% and reduced gene expression of mast cell chymase by 50% compared with AngII infused mice lacking imatinib. Gene expression analysis of SMC marker SM22α demonstrated an increase by 48% together with a more intact medial layer after treatment with imatinib as evaluated with SM22α immunostaining. CONCLUSION: Present findings highlight the importance of tyrosine kinase pathways in the development of AAA. Our results show, that imatinib treatment inhibits essential mast cell, T lymphocyte and SMC mediated processes in experimental AAA. Thus, our results support the idea that tyrosine kinase inhibitors may be useful in the treatment of pathological vascular inflammation and remodeling in conditions like AAA.
BACKGROUND:Abdominal aortic aneurysm (AAA) is characterized by vascular remodeling with increased infiltration of inflammatory cells and apoptosis/modulation of vascular smooth muscle cells (SMCs). Imatinib is a selective inhibitor of several tyrosine kinases, including PDGF receptors, Abl, and c-kit. The objective of this study was to characterize the potential protective role of imatinib on AAA development and the molecular mechanisms involved. METHODS: Male ApoE(-/-) mice were infused with angiotensin (Ang) II (1000 ng/kg/min) for 4 weeks to induce AAA or saline as controls. Daily treatment with 10 mg/kg imatinib, or tapwater as control, was provided via gavage for 4 weeks. RESULTS: Treatment with imatinib was found to decrease the aortic diameter and vessel wall thickness, mediated by multiple effects. Imatinib treatment in AngII infused mice resulted in a reduced cellular infiltration of CD3ε positive T lymphocytes by 86% and reduced gene expression of mast cell chymase by 50% compared with AngII infused mice lacking imatinib. Gene expression analysis of SMC marker SM22α demonstrated an increase by 48% together with a more intact medial layer after treatment with imatinib as evaluated with SM22α immunostaining. CONCLUSION: Present findings highlight the importance of tyrosine kinase pathways in the development of AAA. Our results show, that imatinib treatment inhibits essential mast cell, T lymphocyte and SMC mediated processes in experimental AAA. Thus, our results support the idea that tyrosine kinase inhibitors may be useful in the treatment of pathological vascular inflammation and remodeling in conditions like AAA.
Authors: J Concannon; P Dockery; A Black; S Sultan; N Hynes; P E McHugh; K M Moerman; J P McGarry Journal: J Anat Date: 2019-09-11 Impact factor: 2.610
Authors: Carmela R Balistreri; Silvio Buffa; Alberto Allegra; Calogera Pisano; Giovanni Ruvolo; Giuseppina Colonna-Romano; Domenico Lio; Giuseppe Mazzesi; Sonia Schiavon; Ernesto Greco; Silvia Palmerio; Sebastiano Sciarretta; Elena Cavarretta; Antonino G M Marullo; Giacomo Frati Journal: Oxid Med Cell Longev Date: 2018-04-05 Impact factor: 6.543
Authors: Alicia N Rizzo; Patrick Belvitch; Regaina Demeritte; Joe G N Garcia; Eleftheria Letsiou; Steven M Dudek Journal: Vascul Pharmacol Date: 2020-03-30 Impact factor: 5.773